Autologous Stem Cell Transplantation for Multiple Myeloma: Underutilized but Highly Effective

In the current issue of the Journal, Rosenberg et al. describe the results of a population-based study regarding the role of autologous stem cell transplantation (ASCT) for patients with newly diagnosed multiple myeloma (MM) between 1998 and 2012 (1). This time period represents an important era, noteworthy for the development and implementation of several new classes of efficacious myeloma therapies, including immunomodulatory agents (eg, lenalidomide) and proteasome inhibitors (eg, bortezomib), which called into question the role of autologous stem cell transplantation as consolidation for myeloma patients following induction therapy (1–4).

https://ift.tt/2MfBPuJ